AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day.
| Event: | Oppenheimer Rare & Orphan Disease Summit | ||
| Date: | May 21, 2021 | ||
| Time: | Live Presentation 10:45 AM – 11:25 AM (ET) |
The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay will be available for 90 days. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Summit or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
Now Accepting Nomination Submissions for the Prestigious Annual AwardToronto, Ontario--(Newsfile Corp. - February 4, 2026)…
DRAPER, UTAH / ACCESS Newswire / February 4, 2026 / CenExel, a leading, wholly owned…
BOCA RATON, FL / ACCESS Newswire / February 4, 2026 / GridAI Technologies Corp. (Nasdaq:GRDX),…
Targeting Q1 2026 Launch, Subject to FDA ClearanceKey Highlights:Cartridge & Infusion Set Lots in Production:…
New Market Briefing From Black Book Research Highlights 80% of Surveyed Hospitals Active in EHR…
BOULDER, CO / ACCESS Newswire / February 4, 2026 / Encision Inc. (OTC PINK:ECIA), a…